- First Online:
- 200 Downloads
Sapropterin dihydrochloride (Kuvan®), hereafter referred to as sapropterin, is a synthetic formulation of the active 6R-isomer of tetrahydrobiopterin, a naturally occurring cofactor for phenylalanine hydroxylase. In the EU, sapropterin is approved for the treatment of hyperphenylalaninaemia in patients ≥4 years of age with tetrahydrobiopterin-responsive phenylketonuria (PKU) and in adults and children with tetrahydrobiopterin deficiency who have been shown to be responsive to such treatment. In the US, it is approved to reduce blood phenylalanine levels in patients with hyperphenylalaninaemia due to tetrahydrobiopterin-responsive PKU.
Oral sapropterin effectively lowers blood phenylalanine levels in a proportion of patients with PKU; to date, there are no published efficacy trials of the specific sapropterin formulation under review in patients with tetrahydrobiopterin deficiency. Sapropterin was well tolerated in patients with PKU, although longer-term tolerability data are required. Sapropterin is the first non-dietary treatment for patients with PKU that has been shown in randomized, double-blind trials to be effective in lowering blood phenylalanine levels. Thus, sapropterin provides a promising treatment option for patients with PKU who are tetrahydrobiopterin-responsive.
The mechanism of action of sapropterin in lowering blood phenylalanine levels in patients with PKU has not been fully elucidated, but appears to be related, in part, to its effect in augmenting and stabilizing mutant phenylalanine hydroxylases, resulting in increased clearance of phenylalanine from the body. In tetrahydrobiopterin deficiency, its mechanism of action is presumed to be secondary to replacement of endogenous tetrahydrobiopterin.
In healthy adults, orally-administered sapropterin is absorbed into the bloodstream,reaching maximum concentrations in 3–4 hours. It has a mean elimination half-life of ≈4 hours in healthy adults and, based on a population pharmacokinetic study, 6.7 hours in patients with tetrahydrobiopterin-responsive PKU. Age, from 9 to 49 years, had no effect on key pharmacokinetic parameters.
In an 8-day screening study in patients aged ≥8 years with PKU, ≈20% of patients responded to sapropterin 10mg/kg/day (i.e. were tetrahydrobiopterin responsive). Tetrahydrobiopterin-responsive patients from this study were entered into a randomized, double-blind, placebo-controlled trial in which they received sapropterin 10mg/kg/day or placebo. At the end of 6 weeks of treatment, sapropterin recipients experienced a significant 28% decrease from baseline in mean blood phenylalanine level, while there was no significant change in placebo recipients. The difference in mean blood phenylalanine level between sapropterin and placebo groups was statistically significant at −245 μmol/L. In an extension of this trial, significantly greater reductions in blood phenylalanine levels were observed with sapropterin dosages of 10 and 20 mg/kg/day than with sapropterin 5 mg/kg/day (each dose administered for 2 weeks), indicating a dose dependent effect. During 12 weeks of treatment with the sapropterin dosage individualized to the patient according to the earlier response to sapropterin 5, 10 or 20 mg/kg/day, reductions in plasma phenylalanine were observed in all dosage groups.
In a randomized, double-blind trial in children aged 4–12 years with tetrahydrobiopterin-responsive PKU, patients treated with sapropterin 20 mg/kg/day had reduced blood phenylalanine levels after 3 weeks of treatment. Over the full 10-week trial, sapropterin and placebo recipients experienced a significantly increased tolerance to dietary phenylalanine (20.9 mg/kg/day in sapropterin and 2.9mg/kg/day in placebo recipients).
Sapropterin was well tolerated in patients with PKU. In clinical trials in patients with PKU, the following adverse events were identified: headache, rhinorrhoea (both at a frequency of ≥10%), pharyngolaryngeal pain, nasal congestion, cough, diarrhoea, vomiting, abdominal pain and hypophenylalaninaemia (all at a frequency of ≥1% to <10%). There were no serious adverse events that were thought to be related to sapropterin treatment.
Unable to display preview. Download preview PDF.
- 1.Scriver CR, Levy H, Donlon J. Chapter 77. Hyperphenyla-laninaemia: phenylalanine hydroxylase deficiency. In: Metabolic and molecular bases of inherited disease [on-line]. Available from URL.http://www.ommbid.com/OMMBID/the_online_metabolic_bases_of_inherited_disease/b/fulltoc [Accessed 2009 Jan 12]
- 2.Blau N, Thöny B, Cotton RGH et al. Chapter 78. Disorders of tetrahydrobiopterin and related biogenic amines. In: Metabolic and molecular bases of inherited disease [online]. Available from URL. http://www.ommbid.com/OMMBID/the_online_metabolic_bases_of_inherited_disease/b/fulltoc [Accessed 2009 Jan 12]
- 5.Longo N. Chapter 352. Inherited disorders of amino acid metabolism and storage. in Braunwald E, editor. Harrison's principles of internal medicine (15th edition). New York: McGraw-Hill, 2001: 2301–5Google Scholar
- 8.de Baulny HO, Abadie V, Feillet F, et al. Management of phenylketonuria and hyperphenylalaninemia. J Nutr 2007 Jun; 137 (6 Suppl. 1): 1561–3SGoogle Scholar
- 13.US FDA. Sapropterin dihydrochloride: prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/022181lbl.pdf [Accessed 2008 Aug 5]
- 14.Asubio Pharma Co Ltd. Asubio Pharma's inherited metabolic disease agent Biopten® receives approval for additional indication, 2008 Jul 16 [online media release]. Available from URL: http://www.daiichisankyo.com/4less/cgi-bin/cs4view_obj.php/b_newsrelease_n1_eng/554/080716_001v1-e.pdf [Accessed 2009 Mar 13]
- 15.European Medicines Agency. Kuvan®: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/kuvan/H-943-PI-en.pdf [Accessed 2009 Jan 18]
- 21.US FDA Centre for Drug Evaluation and Research. Sapropterin dihydrochloride review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2007/022181s000_MedR_P1.pdf [Accessed 2008 Aug 1]
- 22.Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 2007 Oct; 30(5): 700–7PubMedCrossRefGoogle Scholar
- 23.Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007 Aug 11; 370(9586): 504–10PubMedCrossRefGoogle Scholar
- 25.Trefz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. Epub 2009 Mar 2Google Scholar
- 26.US National Institutes of Health. Phenylketonuria: screening and management (National Institutes of Health Consensus Development Conference Statement October 16–18, 2000) [online]. Available from URL: http://consensus.nih.gov/2000/2000Phenylketonuria113html.htm [Accessed 2008 Oct 28]
- 28.European Medicines Agency. Committee for Medicinal Products for Human Use assessment report for Kuvan [online]. Available from URL: http://www.emea.eu/humandocs/PDFs/EPAR/kuvan/H-943-en6.pdf [Accessed 2009 Feb 25]
- 31.BioMarin Pharmaceutical. Study of phenoptin in subjects with phenylketonuria who have participated in protocols PKU-004 or PKU-006 [ClinicalTrials.gov identifier NCT00332189]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Mar 5]